Physician profile
Emily Morris
NPI 1851932727
$12,032.78
in general payments reported to CMS, 2019-2025
38 companies · $2,992 in 2025
The $2,992 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $847 · 2022: $2,217 · 2023: $3,002 · 2024: $2,976 · 2025: $2,992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,969.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,972.08 | 2021-2025 | Rexulti, Nuedexta, Abilify Mycite |
| Neurocrine Biosciences, INC. | $1,186.28 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,051.43 | 2021-2025 | Caplyta |
| Abbvie INC. | $991.36 | 2021-2025 | |
| Alkermes, INC. | $921.80 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Takeda Pharmaceuticals U.S.A., INC. | $729.56 | 2021-2025 | Trintellix |
| Corium, LLC | $571.18 | 2021-2025 | Azstarys |
| Axsome Therapeutics, INC. | $552.61 | 2022-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $538.46 | 2021-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $537.06 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Bausch Health US, LLC | $471.73 | 2021-2025 | Aplenzin, Wellbutrin |
| Sunovion Pharmaceuticals INC. | $397.57 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $269.15 | 2022-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $235.01 | 2022-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $189.95 | 2021-2024 | Jornay Pm |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $172.54 | 2024-2025 | Cobenfy |
| Novartis Pharmaceuticals Corporation | $143.13 | 2023-2025 | |
| Tris Pharma INC | $138.66 | 2022-2024 | Dyanavel Xr |
| Noven Therapeutics, LLC | $131.52 | 2023-2025 | Xelstrym, Secuado |
| Idorsia Pharmaceuticals US INC | $93.74 | 2024-2025 | Quviviq, Quviviq |
| Neos Therapeutics, LP | $80.84 | 2021-2023 | Adzenys Xr-Odt |
| Biogen, INC. | $69.58 | 2024-2025 | Zurzuvae |
| Eisai INC. | $60.22 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $59.64 | 2023 | Breztri |
| Indivior INC. | $54.26 | 2022-2023 | Perseris |
| Owp Pharmaceuticals, INC. | $51.28 | 2022-2024 | Subvenite |
| Avanir Pharmaceuticals, INC. | $45.27 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $44.64 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $42.97 | 2023 | Keytruda, Zerbaxa, Recarbrio |
| Neuronetics, INC. | $41.15 | 2022-2023 | Neurostar Tms Therapy System |
| Jazz Pharmaceuticals INC. | $39.12 | 2021 | |
| Mylan Specialty L.P. | $30.83 | 2022 | |
| Adlon Therapeutics L.P. | $28.11 | 2021 | |
| Almatica Pharma LLC | $20.53 | 2021 | |
| Pfizer INC. | $20.51 | 2024 | |
| Aytu Biopharma, INC. | $18.07 | 2021 | |
| Supernus Pharmaceuticals, INC. | $17.60 | 2024 | Qelbree |
| Vertical Pharmaceuticals, LLC | $13.34 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.